Despite the prevalence of KRAS mutations in human cancers, there remain no targeted therapies for treatment. The serine/threonine kinase STK33 has been proposed to be required for the survival of mutant KRAS-dependent cell lines, suggesting that small molecule kinase inhibitors of STK33 may be useful to treat KRAS-dependent tumors. In the present study, we investigated the role of STK33 in mutant KRAS human cancer cells using RNA interference, dominant mutant overexpression and small molecule inhibitors.
, Yihong Zhang 1, 5 , Robert J. Kurzeja In one of these studies, STK33, a poorly characterized kinase, was identified as a candidate drug target for mutant KRAS tumors (3) . STK33 is a serine/threonine kinase that belongs to the calcium/calmodulin-dependent family of kinases (4) . The physiological function of STK33 is unknown and STK33 does not appear to be genetically altered in cancers (3) . However, down-regulation of STK33 by RNA interference (RNAi) or inhibition of its kinase activity by over-expression of a kinase dead (KD) K145M STK33 protein conferred a lethal phenotype to mutant KRAS cell lines (3) . Suppression of STK33 expression by either method resulted in the inhibition of p70S6K and RPS6 phosphorylation, but had no effect on the phosphorylation of AKT, ERK1/2 or mTOR, suggesting that STK33 is downstream from these nodes, but upstream from p70S6K. FLAG). The small interfering RNA (siRNA) oligonucleotides were either commercially available or custom synthesized and are described in Supplementary Materials.
Commercial sources of full-length, active STK33 proteins were from Millipore (catalog # 14-671) and Invitrogen (catalog # PV4343). Full-length STK33 was also produced at Amgen Inc. (see Supplementary Methods). The LANCE® Ultra Kinaselect™ Ser/Thr kit (Perkin Elmer) was used to identify STK33 substrates.
RNA interference and over-expression of STK33
NOMO-1 and SKM-1 cells were transfected with siRNA using Transductin 
Quantification of RNA expression levels
RNA expression levels were determined using the QuantiGene™ branched DNA (bDNA) assay (Affymetrix, Foster City, CA) following the manufacturer's instructions.
The probe sets to detect STK33, KRAS and cyclophilin B RNA are described in Supplementary Methods. Assays were carried out using cell lysates prepared with 1X Quantigene™ Lysis Mixture (Affymetrix).
High throughput siRNA screens
High throughput screens of siRNA libraries were performed in 27 solid tumor cell lines, including cell lines mutant for KRAS. A cell viability assay using CellTiterGlo™ was performed 96 or 120 hours post-transfection. Detailed description of experimental procedures and statistics are found in the Supplementary Methods.
Kinase assays and small molecule library screen
Immuno-precipitation (IP) Kinase Assay: on day 3 post-transfection, DLD-1 cells were lysed on ice in Triton lysis buffer containing fresh protease and phosphate inhibitors. FLAG-STK33 was immuno-precipitated overnight at 4°C in lysis buffer using an anti-FLAG antibody pre-bound to Protein A/G-Plus agarose beads (Santa Cruz Biotechnology). After overnight incubation, the beads were washed extensively in Triton After 90 minutes at 30°C the kinase reactions were stopped by the addition of SDS sample buffer and the samples were run on 10% Tris/glycine gels, fixed and exposed to X-Ray film (Kodak). 
Over-Expression of the Kinase Dead K145M STK33 Has No Effect on the Viability of Mutant KRAS-Dependent Cell Lines
Another approach to study the role of STK33 kinase activity in mutant KRAS cell lines consisted of over-expressing a kinase dead version of STK33 in which the catalytic lysine is mutated to a methione (K145M STK33). DLD-1 and PANC-1 cells were chosen for these experiments because they carry a KRAS mutation (G13D and G12D, respectively) and have been reported to be dependent on KRAS and STK33 for proliferation and survival (3). STK33 protein levels are higher in DLD-1 cells compared to PANC-1 cells, but both cell lines have similar levels of p70S6K and RPS6 phosphorylation ( Supplementary Fig. 4 ). In general, STK33 RNA and protein levels are variable across cell lines and protein levels do not correlate with the levels of p70S6K and RPS6 phosphorylation (Supplementary Fig. 4A and B).
To confirm that K145M STK33 has no catalytic activity, FLAG-tagged wild-type or K145M STK33 were over-expressed in DLD-1 cells by transient transfection, immunoprecipitated and incubated with 33 P γ-ATP. Weak auto-phosphorylation of wildtype STK33 was observed following its over-expression, consistent with published data (3, 5) , but no auto-phosphorylation of K145M STK33 was observed (Fig. 3A ).
Endogenous STK33 kinase activity was low in several cell lines tested suggesting that it is a weak kinase in cells (data not shown). We also tested the purified recombinant K145M STK33 protein in a kinase assay with the p70S6K peptide as a substrate. K145M STK33 was again confirmed to be inactive (Fig. 4B right panel) . We then monitored the effect of over-expression of wild-type or K145M STK33 on the levels of p70S6K and RPS6 phosphorylation and on the viability of DLD-1 and PANC-1 cell lines. Overexpression of wild-type STK33 had no effect on the levels of p70S6K or RPS6 phosphorylation or on the viability of DLD-1 or PANC-1 cells (Fig. 3B-E) . Similarly, over-expression of the K145M STK33 in these two cell lines had no effect on either of these parameters (Fig. 3B-E) .
Identification of Small Molecule STK33 Kinase Inhibitors
To directly address whether the STK33 kinase activity is important for the survival of mutant KRAS cell lines, we developed a high throughput STK33 kinase assay to screen for potent small molecule inhibitors. Since little is known about the potential substrates for STK33 (5), a small commercial set of substrates, including peptides for CREB (CREBtide), p70S6K, Polo-like kinase (PLK), histone H3 and myelin basic protein (MBP), was screened using full-length STK33 proteins from Millipore or Invitrogen. These preliminary experiments showed that the CREBtide and p70S6K peptides were potential substrates for the two separate sources of STK33 (Fig. 4A) . Fulllength STK33 was then expressed and purified by us in sufficient quantities to characterize its enzyme kinetic parameters, to optimize kinase assay conditions and to conduct a high throughput small molecule screen. During assay optimization, we found that the CREBtide peptide was phosphorylated in an STK33-independent fashion (Fig.   4B , left panel and data not shown). Unexpectedly, CREBtide phosphorylation was detected after a kinase reaction in the presence of K145M STK33, suggesting the presence of some contaminant kinase in this preparation. On the other hand, the phosphorylation of the p70S6K peptide was closely linked to the levels of STK33 protein purity and was absent from the K145M STK33 preparation (Fig. 4B , right panel and data not shown) suggesting that p70S6K is a more selective substrate. We therefore screened a small molecule library using an STK33 kinase assay with a p70S6K peptide as a substrate. Over 400 000 small molecules were screened at a concentration of 15 μM.
The hit rate was 0.95% and the confirmation rate was 71%. The compound concentrations that inhibited the kinase activity by 50% (IC 50 ) were determined for the 1043 most potent hits. We identified 6 molecules that inhibited STK33 kinase activity with IC 50 s less than 10 nM and 69 molecules with IC 50 s less than 100 nM ( Table 1) .
Examples of IC 50 curves are shown in Fig. 4C . 
KRAS-Dependent Cell Lines
The STK33 kinase inhibitors were used to determine whether STK33 inhibition has any effect on the phosphorylation of p70S6K or RPS6 in cells. Our preliminary experiments showed that the levels of p70S6K phosphorylation are very low in many cell lines (Fig. 1A and C and Supplementary Fig. 4 ) and are therefore not amenable for quantitative assays. We therefore decided to measure the levels of RPS6 phosphorylation (pRPS6), a well known p70S6K substrate which is inhibited when mutant KRAS is down-regulated ( Fig. 1A and C) . The 510 most potent STK33 kinase inhibitors were tested for their ability to inhibit the phosphorylation of RPS6 in three cell lines, two with mutant KRAS (NB4 and SKM-1) and one wild-type for KRAS as a control (U-87 MG).
Potent inhibition of RPS6 phosphorylation (<100 nM) was observed in all three cell lines ( Fig. 5A and B and Supplementary Table 1) demonstrating that these compounds are cell permeable. However, our results showed no correlation between the effect of the small molecules tested on STK33 kinase activity in the biochemical assay and their effect on the phosphorylation of RPS6 in any of the cell lines tested (Fig. 5A and B and Supplementary Table 1) .
Finally, the 145 most potent STK33 kinase inhibitors were tested in four AML cell lines, two mutant (NB4 and SKM-1) and two wild-type (OCI-AML3 and U937) for KRAS, for their effects on cell viability. First, our data showed no significant correlation between the potency of the compounds on the STK33 kinase activity and on cell viability . 6A-D and Supplementary Table 2) . Second, the effects observed were independent of KRAS mutational status (Fig. 6A-E) . Together, our data do not support a synthetic lethal relationship between KRAS-dependence and STK33.
Discussion
KRAS mutations are an important driver of tumor growth. In the past 15 years, the inhibition of driver mutations, such as those found in several kinases including ABL, KIT, EGFR and B-Raf, has resulted in important clinical advances (6) (7) (8) (9) (10) . However, targeting of other important driver genes such as KRAS has remained elusive. It has long been recognized that blocking the deleterious effects of KRAS mutations would likely be an effective approach to treat cancers that carry KRAS mutations. Since KRAS itself has been difficult to target, several groups have looked for alternative approaches to block KRAS function. Several potential targets have been described recently, mostly through screens for synthetic lethal interactions (3, 11, 12) . We decided to focus on one of these novel targets, STK33, since its kinase activity was documented to be required for the survival of KRAS-dependent cell lines. It is interesting to note that STK33 was a hit in a short hairpin (shRNA) screen to identify essential kinases in 293T cells, which are not KRAS-dependent (13) . On the other hand, STK33 was not identified in another synthetic lethal screen for KRAS dependency (12) , or in our screens (Fig. 2) . Knockdown of KRAS in our screens readily identified KRAS-dependent cell lines (Fig. 2) , demonstrating the robustness of the screens. False-negative results are not uncommon in si/shRNA screens and may be due to the inability to efficiently down-regulate certain genes in high throughput experiments.
Our data confirmed the efficient knockdown of both STK33 and KRAS (Supplementary Fig. 2A and C) , but also suggested off-target effects for two siRNAs, STK33_2Q and STK33_7Q, which inhibited cell viability ( Supplementary Fig. 2 and 3) . The off-target effects of STK33_7Q were not apparent in NOMO-1 and SKM-1 cells (Fig. 1A and C analysis is designed to avoid false-positives associated with single siRNAs that give offtarget effects. Our robust analysis method might also account for the discordance between our data and those previously published. P70S6K and RPS6 phosphorylation was not affected in multiple cell lines despite efficient knockdown of STK33 and efficient over-expression of a kinase dead STK33.
Moreover, across 510 small molecule STK33 kinase inhibitors, there was no correlation between their effect on STK33 kinase activity and their effect on the phosphorylation of RPS6 in any of the cell lines tested. This is not due to a failure of the assay since the most potent inhibitors of RPS6 phosphorylation across all three cell lines tested were potent PI3Kα/mTOR inhibitors (data not shown). PI3Kα/mTOR inhibitors are known to inhibit RPS6 phosphorylation (15). Together these data suggest that p70S6K and RPS6
are not substrates for STK33. During the course of our studies, we performed several experiments to identify additional STK33 substrates without success. First, a ProtoArray® of >9000 full-length proteins was screened using recombinant wild-type versus K145M STK33 proteins, but no clear substrates were identified (data not shown).
It is interesting that a p70S6K peptide that contains threonine 389, the same amino acid whose phosphorylation was shown to be modulated by STK33 down-regulation by Scholl et al., is a substrate for STK33 in our biochemical enzyme assay. However, the full- An optimized STK33 kinase assay, using the p70S6K peptide as a substrate, was used to screen a small molecule compound library of >400 000 molecules. In the initial screen, all molecules were tested at a concentration of 15 μM. The kinase assay was performed using a 22-point dilution of the most 1043 potent compounds to determine their respective IC 50 . CAN-11-0778 against the FLAG tag and incubated with 33 P γ-ATP. 
